GNH USA

Europe — EMA

Ngenla (Somatrogon)

GNH USA supplies Ngenla (Somatrogon), a growth hormone analog for treating growth hormone deficiency in children. Request a quote for global supply today.

Request sourcing

1
Pack/s

What is Somatrogon?

Somatrogon, the active ingredient in Ngenla, is a growth hormone analog presented as an injectable solution for subcutaneous use. It treats growth hormone deficiency in children, helping to promote linear growth and improve height outcomes.

GNH USA supplies Ngenla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Somatrogon used for?

Somatrogon is used in pediatric growth disorders that respond to growth hormone therapy. - Growth hormone deficiency in children: promotes linear growth and increases height velocity. - Idiopathic short stature in children: helps achieve normal growth patterns. - Growth failure associated with chronic kidney disease in pediatric patients: supports growth development.

What are the side effects of Somatrogon?

Somatrogon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema - Headache - Nausea - Peripheral edema - Arthralgia - Fatigue

Serious or Rare Side Effects: - Intracranial hypertension - Slipped epiphysis (growth plate fracture) - Severe allergic reactions (anaphylaxis, urticaria) - Abnormal glucose metabolism or diabetes mellitus - Tumor recurrence or progression - Pancreatitis

What precautions apply to Somatrogon?

Before initiating therapy, clinicians should consider several safety measures. - Dose titration: adjust based on IGF‑1 levels and growth response. - Monitoring: regular assessment of growth parameters, IGF‑1, glucose, and thyroid function. - Contraindications: known hypersensitivity to somatrogon or any excipients. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Long‑term therapy: monitor for scoliosis progression and intracranial pressure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Somatrogon interact with?

Somatrogon can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Glucocorticoids: may antagonize growth‑hormone effects. - Insulin or oral hypoglycemics: may need dose adjustment due to altered glucose metabolism. - Estrogen therapy: can excessively raise IGF‑1 levels.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: monitor thyroid function as GH can increase conversion. - Vitamin D or calcium supplements: watch for hypercalcemia. - Other peptide hormones (e.g., IGF‑1 therapy): assess for additive growth effects.

Frequently asked questions

What is Ngenla used for?+
Ngenla contains somatrogon, a growth hormone analog indicated for the treatment of growth hormone deficiency in children. It helps stimulate linear growth and improve height outcomes when prescribed by a pediatric endocrinologist.
How does somatrogon work?+
Somatrogon binds to growth hormone receptors, activating intracellular signaling that increases production of insulin‑like growth factor‑1 (IGF‑1). Elevated IGF‑1 promotes bone growth, protein synthesis, and overall linear growth in children with deficient endogenous growth hormone.
What is the usual dose of Ngenla?+
The dose of Ngenla is individualized. A qualified prescriber determines the appropriate amount based on the child’s weight, IGF‑1 levels, and growth response, following established clinical guidelines.
Is Ngenla safe during pregnancy or breastfeeding?+
Safety of somatrogon in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk, and typically it is avoided in pregnant or nursing individuals.
How do I order Ngenla from GNH USA?+
Submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.
How does Ngenla compare with other growth hormone products?+
Ngenla (somatrogon) is a long‑acting growth hormone analog that requires less frequent subcutaneous injections compared with daily recombinant GH products. Its efficacy in promoting growth is comparable, while the reduced injection frequency may improve adherence.
What are the storage and handling requirements for Ngenla?+
Ngenla must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.
How is Ngenla administered?+
Ngenla is given as a subcutaneous injection, typically into the thigh or abdomen. The injection site should be rotated with each dose, and the medication must be administered by a trained healthcare professional or caregiver following aseptic technique.
What are the most serious risks associated with Ngenla?+
Serious risks include intracranial hypertension, slipped epiphysis (growth‑plate fracture), severe allergic reactions, abnormal glucose metabolism, and potential tumor recurrence. Patients should be monitored regularly for these adverse events.
Who should not use Ngenla?+
Ngenla is contraindicated in individuals with known hypersensitivity to somatrogon or any of its excipients. It should also be avoided in patients with active malignancy or uncontrolled diabetes unless the prescriber determines that benefits outweigh the risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Somatrogon
Route
Subcutaneous Use
Manufacturer
Pfizer Europe Ma Eeig
Origin
EU

Related products